Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease

Nephrology has benefited from conducting increasingly large high-quality trials in the last 5- 10 years. In addition to the long-standing known benefits of renin-angiotensin system inhibitors, we now have multiple pharmacotherapies that provide kidney and/or cardiovascular protection for certain typ...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों:	Zhu, D, Staplin, N, Haynes, R, Herrington, W, Judge, P
स्वरूप:	Journal article
भाषा:	English
प्रकाशित:	Oxford University Press 2025

समान संसाधन

Kidney disease trials for the 21st century: innovations in design and conduct
द्वारा: Herrington, W, और अन्य
प्रकाशित: (2019)

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
द्वारा: Mayne, K, और अन्य
प्रकाशित: (2024)

Renoprotective effect of pentoxifylline in advanced chronic kidney disease
द्वारा: Chih-Chin Kao
प्रकाशित: (2015-01-01)

Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial
द्वारा: Preiss, D, और अन्य
प्रकाशित: (2022)

The prevention and management of chronic kidney disease among patients with metabolic syndrome
द्वारा: Zhu, D, और अन्य
प्रकाशित: (2025)

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
द्वारा: Staplin, N, और अन्य
प्रकाशित: (2023)

Chronic kidney disease, heart failure and neprilysin inhibition
द्वारा: Haynes, R, और अन्य
प्रकाशित: (2019)

Conventional and genetic evidence on the association between adiposity and chronic kidney disease
द्वारा: Zhu, P, और अन्य
प्रकाशित: (2020)

Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease
द्वारा: Silvie Hojná, और अन्य
प्रकाशित: (2022-10-01)

Comment on: Is the renoprotective effect of erythropoietin in chronic kidney disease a myth?
द्वारा: Mahmoud Rafieian-Kopaei
प्रकाशित: (2014-01-01)

Determining the relationship between blood pressure, kidney function, and chronic kidney disease: insights from genetic epidemiology
द्वारा: Staplin, N, और अन्य
प्रकाशित: (2022)

Modeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease
द्वारा: John S. Clemmer, और अन्य
प्रकाशित: (2023-11-01)

Renoprotective effects of ferric citrate in a mouse model of chronic kidney disease
द्वारा: Mark R. Hanudel, और अन्य
प्रकाशित: (2022-04-01)

Reply to comment on: Is the renoprotective effect of erythropoietin in chronic kidney disease a myth?
द्वारा: Pei-Ying Yeh, और अन्य
प्रकाशित: (2014-01-01)

Editorial: Recent advances on renoprotection and kidney regeneration
द्वारा: Ignacio Gimenez, और अन्य
प्रकाशित: (2023-04-01)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial
द्वारा: Mayne, KM, और अन्य
प्रकाशित: (2024)

Renoprotective effect of febuxostat on contrast-induced acute kidney injury in chronic kidney disease patients stage 3: randomized controlled trial
द्वारा: Iman Ibrahim Sarhan, और अन्य
प्रकाशित: (2023-03-01)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
द्वारा: Herrington, W, और अन्य
प्रकाशित: (2022)

Renoprotective effect of stevia residue extract on adenine-induced chronic kidney disease in mice
द्वारा: Arshad Mehmood, और अन्य
प्रकाशित: (2020-09-01)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
द्वारा: Haynes, R, और अन्य
प्रकाशित: (2018)

PERINDOPRIL: THE POSSIBILITY OF ANTIHYPERTENSIVE AND RENOPROTECTIVE THERAPY
द्वारा: O. V. Dralova, और अन्य
प्रकाशित: (2016-01-01)

Efficacy of Low-Protein Diet and Ketoanalogues of Amino Acids as a Complex of Renoprotective Agents in the Therapy of Chronic Kidney Disease
द्वारा: O.O. Dobrik
प्रकाशित: (2013-08-01)

Effects of empagliflozin on fluid overload, weight and blood pressure in chronic kidney disease
द्वारा: Mayne, K, और अन्य
प्रकाशित: (2023)

Renoprotective opportunities of Lespedeza capitata in patients with chronic kidney disease and type 2 diabetes mellitus
द्वारा: S.V. Kushnirenko, और अन्य
प्रकाशित: (2021-09-01)

Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study
द्वारा: Akinori Yamaguchi, और अन्य
प्रकाशित: (2017-05-01)

TaleNeprilysin and Neprilysin inhibition in chronic kidney disease
द्वारा: Judge, PK, और अन्य
प्रकाशित: (2021)

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
द्वारा: Judge, PK, और अन्य
प्रकाशित: (2024)

Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial
द्वारा: Haynes, R, और अन्य
प्रकाशित: (2018)

The renoprotective effect of Tibolone in sepsis-induced acute kidney injury
द्वारा: Ejder Saylav Bora, और अन्य
प्रकाशित: (2024-11-01)

Evaluating the renoprotective effectiveness of sodium-glucose co-transporter 2 inhibitor therapy in patients with chronic kidney disease: A prospective study
द्वारा: Karadžić-Ristanović Vidna, और अन्य
प्रकाशित: (2024-01-01)

Plausible prediction of renoprotective effects of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney diseases
द्वारा: Alexander E Berezin, और अन्य
प्रकाशित: (2024-02-01)

Inhibition of α2-adrenoceptor is renoprotective in 5/6 nephrectomy-induced chronic kidney injury rats
द्वारा: Kohei Hayashi, और अन्य
प्रकाशित: (2021-01-01)

The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease
द्वारा: Natsumi Tomita, और अन्य
प्रकाशित: (2020-09-01)

Evidence for reverse causality in the association between blood pressure and cardiovascular risk in patients with chronic kidney disease
द्वारा: Herrington, W, और अन्य
प्रकाशित: (2016)

Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: UK Heart and Renal Protection (UK HARP)-III. Rationale, trial design and baseline data
द्वारा: Haynes, R, और अन्य
प्रकाशित: (2016)

THE STUDY OF RENOPROTECTIVE PROPERTIES OF ERYTROPOETIN DERIVATIVES ON THE KIDNEY ISCHEMIA-REPERFUSION MODEL
द्वारा: V. V. Elagin, और अन्य
प्रकाशित: (2018-12-01)

Suppressed renoprotective purines in COVID-19 patients with acute kidney injury
द्वारा: Edwin K. Jackson, और अन्य
प्रकाशित: (2022-10-01)

Diabetic Kidney Disease in Childhood and Adolescence: Conventional and Novel Renoprotective Strategies
द्वारा: Samuel N. Uwaezuoke, और अन्य
प्रकाशित: (2020-07-01)

Diabetic nephropathy. Is renoprotection determined by the choice of hypoglycemic therapy?
द्वारा: A. Y. Babenko, और अन्य
प्रकाशित: (2015-12-01)

Neprilysin inhibition in chronic kidney disease.
द्वारा: Judge, P, और अन्य
प्रकाशित: (2014)